Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update.

IF 2.6 1区医学

Journal of Investigative Medicine Pub Date : 2023-12-29 DOI:10.1136/svn-2023-002998

Liping Liu, Zixiao Li, Hongyu Zhou, Wanying Duan, Xiaochuan Huo, Weihai Xu, Shujuan Li, Ximing Nie, Huihui Liu, Jinjie Liu, Dapeng Sun, Yufei Wei, Guitao Zhang, Weizhuang Yuan, Lina Zheng, Jingyi Liu, David Wang, Zhongrong Miao, Yongjun Wang

{"title":"Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update.","authors":"Liping Liu, Zixiao Li, Hongyu Zhou, Wanying Duan, Xiaochuan Huo, Weihai Xu, Shujuan Li, Ximing Nie, Huihui Liu, Jinjie Liu, Dapeng Sun, Yufei Wei, Guitao Zhang, Weizhuang Yuan, Lina Zheng, Jingyi Liu, David Wang, Zhongrong Miao, Yongjun Wang","doi":"10.1136/svn-2023-002998","DOIUrl":null,"url":null,"abstract":"Background: China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases.Methods: We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee.Results: This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management.Conclusions: This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.","PeriodicalId":48733,"journal":{"name":"Journal of Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10800268/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/svn-2023-002998","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases.

Methods: We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee.

Results: This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management.

Conclusions: This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.

查看原文本刊更多论文

中国卒中学会缺血性脑血管病临床管理指南：执行摘要和 2023 年更新版。

背景：中国是脑卒中发病率最高的国家之一：中国是脑卒中负担最重的国家之一。实施多维管理指南将有助于临床医生开展循证医疗，改善患者预后，减轻社会负担。本次更新的2019年版将为缺血性脑血管疾病的诊断和治疗提供最新的综合建议：我们对截至 2023 年 8 月 31 日的 MEDLINE（通过 PubMed）进行了全面检索。编写小组通过多轮在线和离线讨论确定了建议。每条建议均采用中国卒中学会（CSA）制定的证据分级算法进行分级。结果：本次更新包括对 15 条现有建议的修订和 136 条新建议，涉及卒中救治的以下领域：缺血性脑血管病的紧急评估和诊断、急性期再灌注治疗、潜在机制评估、抗血栓治疗、并发症的预防和治疗、危险因素管理：本指南更新了自2019年起缺血性脑血管病临床管理的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative Medicine MEDICINE, GENERAL & INTERNALMEDICINE, RESE-MEDICINE, RESEARCH & EXPERIMENTAL

自引率

0.00%

发文量

111

期刊介绍： Journal of Investigative Medicine (JIM) is the official publication of the American Federation for Medical Research. The journal is peer-reviewed and publishes high-quality original articles and reviews in the areas of basic, clinical, and translational medical research. JIM publishes on all topics and specialty areas that are critical to the conduct of the entire spectrum of biomedical research: from the translation of clinical observations at the bedside, to basic and animal research to clinical research and the implementation of innovative medical care.